Clinical Trials on Major Bleed in Finland

Total 181 results

Takeda

Completed

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Treatment Outcome

United States, Canada
GlaxoSmithKline

Terminated

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (orvepitant MDD)

Depressive Disorder, Major

United States, Canada
Eli Lilly and Company

Completed

A Study in Adult Patients With Major Depressive Disorder

Depressive Disorder, Major

United States, Finland, Poland, Russian Federation, Argentina
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Migraine | Major Depressive Disorder

United States, Czechia, Finland, Israel, Italy, Russian Federation, Spain, Ukraine, France, Germany, Greece, Poland, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Poland, Finland, Chile, Argentina, Slovakia, Ukraine, Denmark
Janssen Research & Development, LLC

Completed

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Depressive Disorder, Major

United States, Germany, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

Depressive Disorder, Major

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Naurex, Inc, an affiliate of Allergan plc

Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Depressive Disorder, Major

United States
Takeda

Completed

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Depressive Disorder, Major

United States, Ukraine, Germany, Poland, Bulgaria, Finland, Russian Federation
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Takeda

Completed

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Depressive Disorder, Major

United States, Poland, United Kingdom, Russian Federation, Canada
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Depressive Disorder, Major

Taiwan, Germany, Hong Kong, Poland, Malaysia, Romania, Serbia, Ukraine, Japan, Finland, Latvia, Croatia, India, Korea, Republic of, Philippines, Russian Federation
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
Naurex, Inc, an affiliate of Allergan plc

Completed

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Depressive Disorder, Major

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Naurex, Inc, an affiliate of Allergan plc

Completed

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Takeda

Completed

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

United States
Australian and New Zealand Intensive Care Research...
Monash University; University College Dublin; Health Research Board, Ireland; Health... and other collaborators

Recruiting

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

Wounds and Injuries | Trauma | Traumatic Brain Injury | Multiple Trauma | Major Trauma | Traumatic Injury | Penetrating Injury | Blunt Injury

Australia, Ireland, Finland, New Zealand, Slovenia, Germany, Saudi Arabia, Switzerland
Cephalon

Completed

Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

Obstructive Sleep Apnea | Major Depressive Disorder | Sleep Disorders | Dysthymic Disorder

United States
CSL Behring

Completed

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Blood Coagulation Disorders | Acute Major Bleeding

United States, Belarus, Bulgaria, Romania, Russian Federation, Ukraine
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous... and other conditions

United States, Puerto Rico, South Africa
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam

Clinical Trials on Major Bleed in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations